Literature DB >> 28617084

Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.

Gregory S Sawicki1,2, Edward F McKone3, Stefanie J Millar4, David J Pasta4, Michael W Konstan5,6, Barry Lubarsky7, Jeffrey S Wagener8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28617084     DOI： 10.1164/rccm.201608-1678LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  6 in total

1.  Using Negative Control Outcomes and Difference-in-Differences Analysis to Estimate Treatment Effects in an Entirely Treated Cohort: The Effect of Ivacaftor in Cystic Fibrosis.

Authors:  Simon J Newsome; Rhian M Daniel; Siobhán B Carr; Diana Bilton; Ruth H Keogh
Journal:  Am J Epidemiol       Date:  2022-02-19       Impact factor: 4.897

2.  Poor recovery from a pulmonary exacerbation does not lead to accelerated FEV1 decline.

Authors:  Don B Sanders; Zhanhai Li; Qianqian Zhao; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2017-07-29       Impact factor: 5.482

3.  Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.

Authors:  Scott C Bell; Jochen G Mainz; Gordon MacGregor; Susan Madge; Julie Macey; Moshe Fridman; Ellison D Suthoff; Siva Narayanan; Nils Kinnman
Journal:  BMC Pulm Med       Date:  2019-08-13       Impact factor: 3.317

4.  Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.

Authors:  J S Guimbellot; A Baines; A Paynter; S L Heltshe; J VanDalfsen; M Jain; S M Rowe; S D Sagel
Journal:  J Cyst Fibros       Date:  2020-11-25       Impact factor: 5.482

5.  Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.

Authors:  Leona Bessonova; Nataliya Volkova; Mark Higgins; Leif Bengtsson; Simon Tian; Christopher Simard; Michael W Konstan; Gregory S Sawicki; Ase Sewall; Stephen Nyangoma; Alexander Elbert; Bruce C Marshall; Diana Bilton
Journal:  Thorax       Date:  2018-05-10       Impact factor: 9.139

6.  Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012-2016 Experience.

Authors:  Mark Higgins; Nataliya Volkova; Kristin Moy; Bruce C Marshall; Diana Bilton
Journal:  Pulm Ther       Date:  2020-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.